ClinicalTrials.gg

Program

mifomelatide

Its studies are mostly in Colorectal Neoplasms · Cachexia, led by Endevica Bio.

Furthest: phase 2, since Mar 25, 20252 company-led studies, 1 open or runningNext primary completion: Oct 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Endevica Bio21 open or runningphase 2since Mar 25, 2025Jul 28, 2022Oct 2027phase 2 · NCT06937177

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 28, 2022First study: phase 1 study in CachexiaFirst studyNCT05529849 · 76 enrolled · United States
  2. Mar 25, 2025Phase 2 study in Colorectal NeoplasmsNCT06937177 · 120 planned · United States, Canada

Ahead

  1. Oct 2027Primary completion: phase 2 study in Colorectal NeoplasmsNCT06937177

TargetBeta

MC3R →MC4R →read by rule
“A synthetic cyclic peptide antagonist of melanocortin receptor 3 (MC3R) and melanocortin receptor 4 (MC4R), ”NCIt, by rule

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06937177Colorectal Neoplasms · United States, Canada2RecruitingOct 2027120
NCT05529849Cachexia · United States1CompletedDec 12, 202276

How it is read

Names in the registry

  • “TCMCB07”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.